AI is no panacea, but it can have a role in turning artisanal, trial-and-error drug development into a rapid, cost-effective, data-driven process. The post AI Meets Gene Editing: the Path to Plug-and-Play Drug Development appeared first on MedCity News.
Like many Americans who voted for Donald Trump, Jason Rouse hopes the president’s return will mean lower prices for gas, groceries, and other essentials. But Rouse is looking to the federal government for relief from one particular pain point: high health care costs. “The prices are just ridiculous,” said Rouse, 53, a retired Michigan firefighter…
Lantern has publicly released its methodology for calculating surgical savings, and is inviting others to do the same. The post Lantern Unveils Savings Methodology to Increase Transparency for Specialty Care Pricing appeared first on MedCity News.
The biotech IPOs window is now open, but that doesn’t mean every company can go through it. A panel at the BIO Convention in San Diego discussed the steps biotech companies should take if they’re considering a public listing. The post The Things to Think About Before Taking Your Biotech Company Public appeared first on…
These benefits set employees up with the resources and access to manage their health efficiently and proactively while giving employers financial savings throughout the year. The post The Benefits Hierarchy of Needs: Why Employers & Payers Should Prioritize Gut Health Benefits appeared first on MedCity News.
Advanced computing infrastructure will initially support foundation model development for pathomics, drug discovery and precision medicine
One platform predicts clinical demand and automates healthcare logistics, while another startup deploys hospital-wide AI solutions by embedding engineering teams on-site
When President Donald Trump posted a satirical music video on social media in early October depicting his budget director, Russell Vought, as the Grim Reaper lording over Democrats in Congress, public health workers recognized a kernel of truth. Vought has exerted extraordinary control over government spending this year, usurping congressional decisions on how the nation’s…
Insurers are cutting coverage for costly GLP-1 weight loss drugs, sparking backlash from advocates who say they’re vital for treating obesity. The post As Insurers Drop GLP-1 Coverage, Advocates Search for a Hero in Obesity appeared first on MedCity News.
Madrigal Pharmaceuticals has licensed rights to an Arrowhead Pharmaceuticals small-interfering RNA therapy designed to address a particular genetic mutation associated with the fatty liver disease MASH. It’s Madrigal’s fourth business development deal of the past year and the company’s second one involving siRNA therapies. The post Madrigal Pharma Adds Another Genetic Medicine to Its Drug…